住院COVID-19活动性癌症患者血栓与出血发生率
回顾性队列分析连续住院的COVID-19成人患者,比较无癌症组(n=353)与活动性癌症组(n=45)第28天累积血栓和出血发生率,并将死亡作为竞争风险。结果显示两组血栓和出血发生率均较高且相近,活动性癌症组生存期显著更短(P = .038)。
要点
- 第28天血栓累积发生率:无癌症组18.2%,活动性癌症组14.2%。
- 第28天大出血和致死性出血累积发生率:无癌症组20.8%,活动性癌症组19.5%。
- 3例致死性出血均发生于无癌症组,活动性癌症组生存期显著更短(P = .038)。
核心结论
- 住院COVID-19患者中,无论是否合并活动性癌症,血栓和出血的发生率均较高且程度相近。
研究设计与样本
- 回顾性队列分析,连续纳入住院的COVID-19成人患者;活动性癌症定义为既往6个月内接受过抗肿瘤治疗。
- 无癌症组n = 353,活动性癌症组n = 45;血栓或出血累积发生率以死亡作为竞争风险进行估计。
主要发现
- 第28天血栓累积发生率:无癌症组18.2%(95%CI 10.2%-27.9%),活动性癌症组14.2%(95%CI 4.7%-28.7%)。
- 第28天大出血和致死性出血累积发生率:无癌症组20.8%(95%CI 12.1%-31.0%),活动性癌症组19.5%(95%CI 5.5%-39.8%)。
- 3例致死性出血均发生于无癌症组。
- 活动性癌症组生存期显著更短(P = .038)。
- 最常见恶性肿瘤为淋巴系统肿瘤(17.8%)、胃肠道肿瘤(15.6%)、肺癌(13.3%)和泌尿生殖系统肿瘤(13.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease-2019 (COVID-19) is a recognized prothrombotic state. Patients hospitalized with active cancer are predisposed to thrombosis but whether active cancer further amplifies thrombotic risk with COVID-19 is not known. OBJECTIVES: To evaluate cumulative incidences of thrombotic and hemorrhagic events in hospitalized COVID-19 patients with and without active cancer at 28 days. METHODS: A retrospective cohort analysis of consecutive adults hospitalized with COVID-19 was performed. Active cancer required cancer-directed therapy within previous 6 months. The cumulative incidences of thrombosis or hemorrhage were estimated considering death as a competing risk. RESULTS: Patients without cancer (n = 353) and active cancer (n = 45) were comparable in terms of age, sex, antibiotics administered, length of hospitalization, and critical care. The most common malignancies were lymphoid (17.8%), gastrointestinal (15.6%), lung (13.3%), and genitourinary (13.3%). At day 28, the cumulative incidence of thrombotic events was 18.2% (95% confidence interval [CI], 10.2%-27.9%) in the non-cancer cohort and 14.2% (95% CI, 4.7%-28.7%) in the cancer cohort. The cumulative incidence of major and fatal bleeding at day 28 was 20.8% (95% CI, 12.1%-31.0%) in the non-cancer group and 19.5% (95% CI, 5.5%-39.8%) in the cancer cohort. Three patients experienced fatal bleeds, all of whom were in the non-cancer cohort. Survival was significantly shorter in the group with active cancer (P = .038). CONCLUSIONS: We observed a similarly high incidence of thrombosis and bleeding among patients admitted with COVID-19 with or without active cancer.
引用
- Patell R, Bogue T, Bindal P, et al. Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19. J Thromb Haemost. 2020. PMID: 32692862. doi:10.1111/jth.15018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。